<SEC-DOCUMENT>0000950123-16-017768.txt : 20160908
<SEC-HEADER>0000950123-16-017768.hdr.sgml : 20160908
<ACCEPTANCE-DATETIME>20160525164222
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-16-017768
CONFORMED SUBMISSION TYPE:	DRSLTR
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20160525

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Medpace Holdings, Inc.
		CENTRAL INDEX KEY:			0001668397
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				320434904
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRSLTR

	BUSINESS ADDRESS:	
		STREET 1:		5375 MEDPACE WAY
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45227
		BUSINESS PHONE:		(513) 579-9911

	MAIL ADDRESS:	
		STREET 1:		5375 MEDPACE WAY
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45227
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRSLTR
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS Letter</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gregory P. Rodgers</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Direct Dial:
212-906-2918</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">greg.rodgers@lw.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">53rd at Third</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">885 Third Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York&nbsp;10022-4834</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tel:&nbsp;+1.212.906.1200&nbsp;Fax:&nbsp;+1.212.751.4864</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">www.lw.com</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g125783img1.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">FIRM&nbsp;/&nbsp;AFFILIATE&nbsp;OFFICES</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May 25, 2016</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>VIA EDGAR AND OVERNIGHT DELIVERY</U></I></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United States Securities and Exchange Commission</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street,
N.E.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Kathleen Suellentrop
and James Lopez</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barcelona</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beijing</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brussels</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Century&nbsp;City&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chicago</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dubai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">D&uuml;sseldorf</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frankfurt</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamburg</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hong Kong</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Houston</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Los&nbsp;Angeles</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Madrid</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Milan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moscow</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Munich</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New&nbsp;Jersey</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New&nbsp;York</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Orange&nbsp;County</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paris</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Riyadh</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rome</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San&nbsp;Diego</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San&nbsp;Francisco</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Silicon&nbsp;Valley</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tokyo</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Washington,&nbsp;D.C.</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"><B>Medpace Holdings, Inc.</B> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;<B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>Draft Registration Statement on Form S-1</B> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Originally Confidentially Submitted March 15, 2016</B> </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CIK No. 0001668397</B> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On behalf of our client Medpace Holdings, Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), and pursuant to the applicable
provisions of the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), and the rules promulgated thereunder, please find enclosed for confidential submission with the Securities and Exchange Commission (the
&#147;<B><I>Commission</I></B>&#148;) a complete copy of Amendment No. 2 (&#147;<B><I>Amendment No. 2</I></B>&#148;) to the above-captioned Draft Registration Statement on Form S-1 (as amended, the &#147;<B><I>Registration Statement</I></B>&#148;),
which was initially submitted to the Commission on a confidential basis pursuant to Title I, Section 106 under the Jumpstart Our Business Startups Act on March 15, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This amendment reflects certain revisions to the Registration Statement in response to the comment letter from the staff of the Commission
(the &#147;<B><I>Staff</I></B>&#148;) to Jesse J. Geiger, the Company&#146;s Chief Financial Officer, dated May 6, 2016. The responses provided herein are based on information provided to Latham &amp; Watkins LLP by the Company. For your convenience
we are also providing five copies of Amendment No. 2, marked to show changes against Amendment No. 1 to the Registration Statement, in the traditional non-EDGAR format. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The numbered paragraphs in italics below set forth the Staff&#146;s comments together with the Company&#146;s responses. Unless otherwise
indicated, capitalized terms used herein have the meanings assigned to them in the Registration Statement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May 25, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 2
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g125783img2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Prospectus Summary, page 1 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note the free cash flow numbers for 2014 and 2015 on page 18. Please advise us regarding the reasons for different numbers on page 31 of the materials provided in response to comment 1. </I></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully acknowledges the Staff&#146;s comment and advises the Staff that the Company revised its definition
of Free Cash Flow subsequent to its presentation of the referenced materials in consideration of SEC guidance on the use of non-GAAP financial measures in Item 10(e)(1)(ii) of Regulation S-K. In addition, we believe the revised definition more
accurately reflects Free Cash Flow available to service debt and enhances comparability of this metric with that of other publically traded peers. The Company notes that this presentation was given in January 2016, and thoughts around how to best
present this metric evolved after the presentation and prior to the confidential submission of the initial Draft Registration Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">The definition of Free Cash Flow was revised by (i) removing the add back of cash interest, excluding interest related to corporate campus
lease payments, and (ii) the campus lease payment reduction was revised to only include the principal portion. As defined in footnote (c) on page 19 of Amendment No. 2, the campus lease payments represent cash rental payments on two corporate
headquarter buildings that are accounted for as deemed assets and subject to depreciation expense over the life of the lease. Payments made for leases are accounted for with a principal portion and an interest portion, consistent with deemed
landlord liability accounting. For purposes of Free Cash Flow, the interest portion of these payments is included in net cash provided by operating activities in our statement of cash flows. The principal portion is reflected as a financing activity
in our statement of cash flows. These adjustments for purposes of arriving at Adjusted EBITDA, Adjusted Net Income and Free Cash Flow have the effect of presenting these leases consistently with all other office leases rentals that we have globally.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations, page 58 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>Please revise or advise us why you do not separately address your labs unit, which appears to be a material part of your operations as presented in the materials provided in response to comment 1.
</I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully acknowledges the Staff&#146;s comment and advises that the Company considers
laboratory service offerings as one of several integral components of its full service clinical development outsourcing model, as described throughout Amendment No. 2. We therefore believe it does not warrant separate discussion in the
Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations (the &#147;MD&amp;A&#148;) section. The Company believes that its current disclosure in the MD&amp;A accurately reflects events, transactions and economic
changes that materially affected the amount of reported revenues, as well as any known trends or uncertainties that may affect future results. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May 25, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 3
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g125783img2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Over the periods presented in the MD&amp;A,&nbsp;laboratory related service offerings have
consisted of 13%, 15%, 15% and 14% of consolidated service revenue, net for the Successor year ended December 31, 2015, the Successor nine month period ended December 31, 2014, the Predecessor three month period ended March 31, 2014 and the
Predecessor year ended December 31, 2013, respectively.&nbsp;Note that a significant portion of revenues included in the above percentages relate to laboratory services performed as a component of a full service clinical development arrangement with
the Company that includes multiple other service offerings, as outlined on pages 94 to 96 in Amendment No. 2.&nbsp;When factoring in contracts that are only laboratory service offering related and do not also include other service offerings,
stand-alone laboratory revenues consistently represent less than 10% of consolidated service revenue, net in all periods presented.&nbsp;Because laboratory only service revenue is relatively consistent and is immaterial compared to revenue as a
whole, the Company does not believe that it is a material driver of any component of its results of operations, and it should not be noted separately in the MD&amp;A. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Prospectively, the Company will analyze all drivers of reported results and known trends and uncertainties, and if laboratory specific service
offerings are determined to materially impact any of these metrics, they will be appropriately disclosed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Business, page 81 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note your response to comment 15. Please revise here or where appropriate to indicate, as explained in your response, that you expect the use of risk sharing arrangements to be very limited and that they are not a
part of your core growth strategy. </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully acknowledges the Staff&#146;s comment and
has revised its disclosure on page 96 of Amendment No. 2 accordingly. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note the revised disclosure in response to comment 17 and the reference to GCP as one example of regulations directly applicable to you. Please revise to clarify the extent to which regulations on the following
are generally directly applicable to you: &#147;the approval process, manufacturing, safety, labeling, storage, record keeping and marketing.&#148; </I></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully acknowledges the Staff&#146;s comment and notes that it is responsible for complying with and
following all regulations applicable to the services the Company provides in connection with the execution of pre-clinical studies and clinical trials, including monitoring clinical trials, data and laboratory analysis, electronic data capture,
patient recruitment, safety reporting, and other related services. The Company does not engage in manufacturing, safety, labeling, storage, record keeping or marketing of medical drugs or devices after the clinical trial process, which are the
responsibility of its customers to the extent they receive approval for such drugs or devices.&nbsp;Additionally, the Company notes that while it may be responsible for safety reporting, maintaining study drugs and maintaining clinical trial records
in connection </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May 25, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 4
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g125783img2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
with the execution of pre-clinical studies and clinical trials on behalf of its customers, these activities are part of the broader regulatory framework relating to pre-clinical studies and
clinical trials. The Company believes that its current disclosure on page 98 of Amendment No. 2, as well as the rest of its disclosure under the heading &#147;Business&#151;Government Regulation,&#148; adequately describes this regulatory framework
for investors and is consistent with the level of disclosure of other companies in its industry. The Company has revised its disclosure on page 98 of Amendment No. 2 to further clarify the extent to which regulations on certain activities apply to
the Company or its customers. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Executive and Director Compensation, page 103 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>5.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We note that you have disclosed compensation only for fiscal year 2015 in the Summary Compensation Table. Please advise why you do not include compensation for fiscal year 2014 pursuant to Item 402(n) of Regulation
S-K. </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully submits, per instruction one to Item 402(n) of Regulation S-K, that it is
not required to provide 2014 fiscal year compensation information in the Summary Compensation Table, because it was not a reporting company pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (15 U.S.C. 78m(a) or
78o(d)), at any time during 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Consolidated Financial Statements </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Note 3. Summary of Significant Accounting Policies </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Reportable Segments, page F-11 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>6.</I></TD>
<TD ALIGN="left" VALIGN="top"><I>We read your response to comment 26. Your CODM assesses your revenue, backlog and net awards by service offering. Please tell us in detail the nature of each of these service offerings and describe for us the
differences between each service offering. Please also tell us why the CODM separately assesses the revenues of each service offering. Alternatively, please disclose your revenues for each type of service or group of similar services offered for
each period presented. See ASC 280-10-50-40. </I></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B>Response</B>: The Company respectfully acknowledges the Staff&#146;s
comment and has revised its disclosure on page F-40 of Amendment No. 2 to disclose revenues for each type of service or group of similar services.&nbsp;The Company will continue to assess revenues by service or group of similar services
prospectively for disclosure in compliance with ASC 280-10-50-40. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May 25, 2016 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B> Page
 5
 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g125783img2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We hope that the foregoing has been responsive to the Staff&#146;s comments and look forward
to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at (212) 906-2918 with any questions or further comments you may have regarding this filing or if you wish to discuss the above. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Gregory P. Rodgers</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Gregory P. Rodgers</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">of LATHAM &amp; WATKINS LLP</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enclosures </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">cc: (via
e-mail) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. August J. Troendle, Chief Executive Officer, Medpace Holdings, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jesse J. Geiger, Chief Financial Officer, Medpace Holdings, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen P. Ewald, Esq., General Counsel, Medpace Holdings, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Howard A. Sobel, Esq., Latham &amp; Watkins LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Glenn R.
Pollner, Esq., Gibson, Dunn &amp; Crutcher LLP </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g125783img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g125783img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ % #Q P$1  (1 0,1 ?_$ (,   (" @(#
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M)9I@<9H(O&JEPWX[5.F;1AW@,>OC;I+<O0*G;S/""2 ,NI2&YJBIE,5PR*&
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M2EE#67,P:8U24RJ2ZFB75T&,$5:3T$F<:T2PI+=)/Q&IYPY!("P@!):M\?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g125783img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g125783img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ #P"H P$1  (1 0,1 ?_$ &$   ,! 0$
M      8("0<%"@$!                     !    <! 0 !!0 # 0
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&*?@2P__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
